[Pyr1]-Apelin-13

Research use only, not for human use.

[Pyr1]-Apelin-13 is a potent and selective endogenous Apelin receptor (APJ) agonist.[Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions[1].[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction.

[Pyr1]-Apelin-13 is a potent and selective endogenous Apelin receptor (APJ) agonist.[Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions[1].[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI.

——

——

[pGlu1]-Apelin-13

Others

Other Targets

endogenous apelin receptor

——

——

217082-60-5

1533.8

C69H108N22O16S

>98% (HPLC)

H2O:50 mg/mL (32.60 mM)

CSCCC(NC(=O)C1CCCN1C(=O)CNC(=O)C(CCCCN)NC(=O)C(CC1=CNC=N1)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C1CCCN1C(=O)C(CCCNC(N)=N)NC(=O)C1CCC(=O)N1)C(=O)N1CCCC1C(=O)NC(CC1=CC=CC=C1)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years